The discovery that aggressive prostate cancer cells hijack their own serotonin production to fuel tumor progression represents a fundamental shift in understanding how neurotransmitters influence cancer biology. This finding could unlock new therapeutic approaches for patients facing one of prostate cancer's most lethal subtypes.
Neuroendocrine prostate cancer (NEPC) cells manufacture serotonin internally using the enzyme aromatic L-amino acid decarboxylase, then recycle it through specialized transporters. The accumulated serotonin directly modifies histones through a process called serotonylation at the H3K4me3Q5 site, essentially rewriting the cancer cell's genetic instruction manual. This epigenetic reprogramming transforms ordinary prostate cells into aggressive neuroendocrine variants that resist standard hormone therapies by suppressing androgen receptor signaling.
The therapeutic implications extend beyond basic biology. Researchers demonstrated that carbidopa, an FDA-approved drug currently used for Parkinson's disease, effectively blocks serotonin synthesis in cancer cells. In both engineered mouse models and human tumor samples transplanted into laboratory animals, carbidopa treatment significantly reduced tumor growth and extended survival times.
This represents a rare convergence where fundamental cancer biology research immediately translates to clinical potential. Unlike many cancer discoveries that require years of drug development, carbidopa's existing safety profile could accelerate clinical trials for NEPC patients. The work also suggests that other neurotransmitter-driven epigenetic mechanisms may operate across different cancer types, potentially opening entirely new categories of precision oncology targets. For a cancer subtype with historically poor outcomes, this serotonin axis offers genuine hope for improved patient survival.